Gsk Plc Stock Current Valuation
| G1SK34 Stock | BRL 41.07 0.29 0.71% |
Valuation analysis of GSK plc helps investors to measure GSK Plc's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that GSK Plc's price fluctuation is very steady at this time. Calculation of the real value of GSK plc is based on 3 months time horizon. Increasing GSK Plc's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since GSK Plc is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GSK Stock. However, GSK Plc's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 41.07 | Real 35.82 | Hype 41.07 | Naive 43.0 |
The real value of GSK Stock, also known as its intrinsic value, is the underlying worth of GSK plc Company, which is reflected in its stock price. It is based on GSK Plc's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of GSK Plc's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of GSK plc helps investors to forecast how GSK stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GSK Plc more accurately as focusing exclusively on GSK Plc's fundamentals will not take into account other important factors: GSK plc Company Current Valuation Analysis
GSK Plc's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current GSK Plc Current Valuation | 484.56 B |
Most of GSK Plc's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GSK plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, GSK plc has a Current Valuation of 484.56 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-General industry. The current valuation for all Brazil stocks is significantly lower than that of the firm.
GSK Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GSK Plc's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GSK Plc could also be used in its relative valuation, which is a method of valuing GSK Plc by comparing valuation metrics of similar companies.GSK Plc is currently under evaluation in current valuation category among its peers.
GSK Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 484.56 B | |||
| Shares Outstanding | 4.09 B | |||
| Price To Book | 2.60 X | |||
| Price To Sales | 9.93 X | |||
| Revenue | 34.11 B | |||
| Gross Profit | 19.92 B | |||
| EBITDA | 8.6 B | |||
| Net Income | 4.38 B | |||
| Total Debt | 19.76 B | |||
| Book Value Per Share | 5.25 X | |||
| Cash Flow From Operations | 7.95 B | |||
| Earnings Per Share | 6.69 X | |||
| Price To Earnings To Growth | 0.45 X | |||
| Number Of Employees | 10 | |||
| Beta | 0.28 | |||
| Market Capitalization | 388.07 B | |||
| Total Asset | 79.1 B | |||
| Z Score | 11.4 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 79.1 B | |||
| Last Dividend Paid | 0.61 |
About GSK Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GSK plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GSK Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GSK plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GSK Stock
GSK Plc financial ratios help investors to determine whether GSK Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.